Gene Logic Inc: An Overview of Our Capabilities
Gene Logic goal is to be the drug development partner of choice for the pharmaceutical and biotechnology industries by providing a unique portfolio of drug discovery and development solutions. Our capabilities span the drug development pipeline and address some of the most important issues in drug development today - productivity, safety, and enhancing late-stage pipelines. Gene Logic consists of three business units: Genomics and Toxicogenomics Solutions, Nonclinical Services, and the Drug Repositioning and Selection™ Program.

Genomics and Toxicogenomics
Pharmaceutical and biotechnology companies worldwide trust Gene Logic's proven portfolio of Genomics and Toxicogenomics solutions and outsourcing services to help accelerate their drug development process. Utilizing our scientific expertise and genomics informatics capabilities, we have built a portfolio of gene expression reference and clinical database systems and software, as well as gene expression and genotyping microarray data generation outsourcing services, designed to meet a variety of economic needs and application support for:

• Microarray Data Generation and Analysis
• Drug Target and Biomarker Discovery within and across species
• Mechanism of Disease
• Predictive Toxicology
• Patient and Drug Indication Selection

Our Genomics solutions utilize thousands of genomics samples characterized by hundreds of clinical parameters and encompass key therapeutic areas, such as onocologic, metabolic, cardiovascular, central nervous system, and inflammatory diseases. All Gene Logic's Genomics solutions are based on the comprehensive genome-wide gene expression data contained in the BioExpress® System. This industry-leading database contains histopathology, clinical chemistry, hematology, treatment, follow-up and many other clinical details for over 19,000 clinically-defined tissue, blood, and cell samples from human clinical studies and complimentary animal models. In a single platform, all of the phenotypic, clinical and experimental information is coupled seamlessly with high-quality Affymetrix GeneChip® microarray gene expression data. The software analysis tools enable researchers to maximize the benefit of the BioExpress® System data to quickly reach powerful conclusions and formulate hypothesis. Our Genomic solutions include:

• BioExpress® System - industry-leading database of >19,000 individual samples
• BioExpress® Data Suites in key therapeutic areas- small data sets
• ASCENTA® System - Web based software featuring summary statistics of human and animal samples
• SCIANTISTM System - Academic and non-profit version of ASCENTA System
• Genesis Enterprise System® Software - data management and analysis software

Gene Logic's Toxicogenomics solutions utilize our extensive collection of gene expression profiles of treated rat tissues and primary cells of greater than 14,000 samples. Treated samples are obtained from carefully designed studies using well characterized pharmaceuticals and chemicals to develop products and services that address toxicology issues. Predictive toxicogenomics algorithms have been built and validated using this extensive data set. These algorithms are used to predict potential human toxicity from rat data. Additional applications include assessing human risk, issue resolution and prioprization of lead compounds, all to enhance your understanding of your compound effects and to help make better informed product decisions. Gene Logic's Toxicogenomics Solutions include:

• ToxExpress® System - a premier reference data set of gene expression and toxicology data
• ToxSuite™ Data Sets specific for target organs or cell - small data sets
• ToxShield™ Suite - software for predictive toxicogenomics
• ToxScreen™ Reports - Outsource Service for screening lead compounds
• Mechanism of Toxicity (MOT) Reports - Outsource service for biological profiling of toxicity of lead compounds

Specifically ToxExpress Solutions can:

• Provide guidance, support and confirmation for candidate chose and non-clinical safety studies, issues management and risk assessment
• Provide the statistical framework to build, test and validate predictive models. Gene Logic has leveraged this same data set to create, test and validate our proprietary models for liver, heart and kidney toxicities, with the goals of predicting human adverse events.
• Provide In-depth whole genome analysis that pinpoints the cascade of events leading to toxic injury within a species or across multiple species (rat, canine, human)
• Provide reference ranges of normal variation across hundreds of compounds and thousands of vehicle control samples
• Establish statistical confidence in data analysis and interpretation based on n=3 or more rule

Microarray Data Generation and Analysis™ Services
Gene Logic is the world's largest commercial Affymetrix GeneChip® facility with significant experience processing more than 40,000 biological samples over 160,000 microarrays. Our Microarray Data Generation and Analysis Service lets you outsource your gene expression and SNP data generation projects to the world's premier commercial microarray data generation operation. With comprehensive data processing and analysis capabilities, a wide range of specialized biotechnical services and bioinformatics expertise, we provide a very high quality, secure, cost-effective service for generating and managing collections of proprietary gene expression data from your clinical and biological samples.

Nonclinical Services
Gene Logic provides a broad portfolio of Nonclinical Services to assist drug developers with compound evaluation, from selection through clinical development. We conduct nonclinical studies of all sizes and degrees of complexity in our 100,000 square feet of laboratory and support space. Studies are backed by in-house pathology, clinical pathology and histopathology capabilities. Areas of study expertise include:

• General Toxicology
• Developmental and Reproductive Toxicology
• Safety Pharmacology
• Vaccine Development

Drug Repositioning and Selection™ Program
Through our Drug Repositioning and Selection™ (DRS™) Program, Gene Logic provides the pharmaceutical industry a unique cost-effective, low-risk partnering solution for finding new uses for your discontinued compounds, prioritizing your most promising lead candidates and finding the broadest therapeutic applications for your marketed compound lifecycle. Our partnerships are flexible, full service collaborations providing pharma the ability to share risk while working together to achieve success. Partners receive full access to our dedicated team of industry-leading drug developers and our comprehensive, multi-prong drug repositioning and selection technology platform.